Navigation Links
SGX Pharmaceuticals Announces Financial Results for the Three and Nine Months Ended September 30, 2007
Date:11/13/2007

or partnerships, the partnering of its research and development programs, competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, the level of resources that its collaborative partners devote to development of its product candidates, the scope and validity of patent protection for its products, and its ability to obtain additional funding to support its operations. For a discussion of these and other factors, please refer to the risk factors described in the Company's annual report on Form 10-K for the year ended December 31, 2006, the Company's quarterly report on Form 10-Q for the three and nine months ended September 30, 2007, as well as other filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward- looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and SGX undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

SGX PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

(unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

2007 2006 2007 2006

Revenue:

Collaborations and

commercial agreements $5,444 $5,014 $16,813 $13,192

Grants 2,142 1,753 10,247 6,151

Total revenue 7,586 6,767 27,060 19,343

Expenses:

Research and development 10,465 8,58
'/>"/>

SOURCE SGX Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... CanAm Enterprises, LLC (“CanAm”) is ... the past month! I-829 approvals have been granted to investors in four different CanAm ... Kimpton Lafayette Hotel project in Philadelphia, and the Valley Forge Convention Center project in ...
(Date:7/29/2015)... ... 2015 , ... July is National UV Awareness Month, and in honor of this month, Dr. ... to protect skin from the sun, as well as how to best treat existing sun ... the most common skin conditions in America. Many people do not protect their skin sufficiently ...
(Date:7/29/2015)... ... ... A June 10, 2015 article from the News-Press, entitled " It's Never ... regular skin cancer screenings from an early age. Skin cancer can strike at any ... skin cancer is rarely fatal; however, if left alone for too long, the fatality ...
(Date:7/29/2015)... ... , ... Employee Fiduciary, LLC announces the launch of its new, online Financial ... plans administered, years in business, and credentials of all Employee Fiduciary financial advisor ... Employee Fiduciary. A search can be done by zip code so a plan sponsor ...
(Date:7/29/2015)... ... July 29, 2015 , ... Several years ago, in order to be ... Little City took a proactive stance and began planning the Children’s Village consisting of ... valuable support to building the third home. , “We are very pleased to have ...
Breaking Medicine News(10 mins):Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 3Health News:July is UV Awareness Month: Learn Top Tips from a Prominent Dermatologist this National UV Awareness Month 2Health News:July is UV Awareness Month: Learn Top Tips from a Prominent Dermatologist this National UV Awareness Month 3Health News:Get Checked for Skin Cancer Early and Often 2Health News:Get Checked for Skin Cancer Early and Often 3Health News:Employee Fiduciary Launches Financial Advisor Directory 2Health News:Little City Receives $500,000 Matching Grant from The Coleman Foundation 2Health News:Little City Receives $500,000 Matching Grant from The Coleman Foundation 3
... ANGELES, April 15 Over the past two months, ... of Aging along with contracted vendors and service providers, ... senior" by participating in a series of hands-on ... the physical challenges facing the elderly. "The program is ...
... The study, reported in the April 16 issue of the ... California, San Francisco and the Stanford University School of Medicine, ... understanding neurodegenerative disease." , ... (Vocus) ...
... Patrick J. Dugan is the new chief legal officer ... this capacity, Dugan will manage the internal legal staff ... has served as lead outside counsel to Medical Mutual,s ... firm, Squire Sanders. Among Dugan,s career accomplishments are his ...
... techniques -- most notably, laparoscopy -- traditional open ... the United States for people with diseases of ... option is a hybrid -- hand-assisted laparoscopic surgery ... compares favorably with standard laparoscopy, according to a ...
... Software Complies with 100% of Updated Interoperability RequirementsTAMPA, ... a leading provider of electronic health records, today ... Technology (CCHIT(R)) has approved Sage,s product, Sage Intergy ... Ambulatory EHR , additionally certified ...
... Medical Groups Are Favorably Managing Turnover According to ... One silver lining to the current economic ... off retirement, for now. However, with the ... future, medical groups are sharpening their competitive edge ...
Cached Medicine News:Health News:SCAN Health Plan Provides 'Senior Sensitivity Training' to City of Los Angeles Department of Aging and Network Service Providers 2Health News:SCAN Health Plan Provides 'Senior Sensitivity Training' to City of Los Angeles Department of Aging and Network Service Providers 3Health News:UCSF, Stanford Study Reveals Neural Networks Targeted in Brain Diseases 2Health News:UCSF, Stanford Study Reveals Neural Networks Targeted in Brain Diseases 3Health News:UCSF, Stanford Study Reveals Neural Networks Targeted in Brain Diseases 4Health News:Helping hand of hybrid surgery benefits colorectal patients 2Health News:Sage Intergy EHR Receives 08 CCHIT Certification 2Health News:Sage Intergy EHR Receives 08 CCHIT Certification 3Health News:Sage Intergy EHR Receives 08 CCHIT Certification 4Health News:Sage Intergy EHR Receives 08 CCHIT Certification 5Health News:The Economy Plus Flexibility Keep Physicians in Practice 2Health News:The Economy Plus Flexibility Keep Physicians in Practice 3Health News:The Economy Plus Flexibility Keep Physicians in Practice 4
(Date:7/29/2015)... REDMOND, Washington , 29. Juli 2015 ... deutschen Diabeteszentrums wurde festgestellt, dass die tägliche ... von Nutraceutix die menschliche Darmflora anreichert und ... Insulinsekretion erhöhen. Die Studie umfasste die tägliche ... (ATCC-Stamm SD-5865) in Tablettenform unter Verwendung der ...
(Date:7/29/2015)... 29, 2015 Touro College has announced that it ... for one of five media marijuana licenses to be issued ... of Health (DOH).  If CanniCare is selected, ... "Our college is supportive of medicinal development ... the Touro College System. "There is still a great deal ...
(Date:7/29/2015)... , July 29, 2015  AcelRx Pharmaceuticals, ... company focused on the development and commercialization of ... breakthrough pain, today announced that it will release ... Monday, Aug 3rd, 2015. AcelRx management will host ... Time (1:30 p.m. Pacific Time) on Aug 3rd, ...
Breaking Medicine Technology:Klinischer Nachweis erbracht, dass L. reuteri Probiotikum von Nutraceutix den Darm-Insulinmetabolismus moduliert 2Touro College Announces Support for CanniCare's Medical Cannabis License Application 2AcelRx Pharmaceuticals to Hold Business Update and Second Quarter Financial Results Conference Call and Webcast on Monday, Aug. 3rd, 2015. 2AcelRx Pharmaceuticals to Hold Business Update and Second Quarter Financial Results Conference Call and Webcast on Monday, Aug. 3rd, 2015. 3AcelRx Pharmaceuticals to Hold Business Update and Second Quarter Financial Results Conference Call and Webcast on Monday, Aug. 3rd, 2015. 4
... at TCT 2007; EVEREST II Study ... Enrollment Continues, ... a successful result with the percutaneous MitraClip device did not need,mitral ... improved function of the left ventricle (commonly known,as reverse remodeling), according ...
... Wyeth,Pharmaceuticals, a division of Wyeth (NYSE: WYE ... Administration (FDA) has accepted for filing the,Company,s supplemental ... (tigecycline) for the treatment of patients with,community-acquired pneumonia ... of,the application. The FDA may approve or disapprove ...
Cached Medicine Technology:New Data Shows Ongoing Benefits of Percutaneous MitraClip(R) Device for Patients With Mitral Regurgitation 2New Data Shows Ongoing Benefits of Percutaneous MitraClip(R) Device for Patients With Mitral Regurgitation 3New Data Shows Ongoing Benefits of Percutaneous MitraClip(R) Device for Patients With Mitral Regurgitation 4New Data Shows Ongoing Benefits of Percutaneous MitraClip(R) Device for Patients With Mitral Regurgitation 5FDA Accepts Wyeth's Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia 2FDA Accepts Wyeth's Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia 3FDA Accepts Wyeth's Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia 4FDA Accepts Wyeth's Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia 5FDA Accepts Wyeth's Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia 6
... balloon. ,The first outside-the-balloon, dual-wire dilatation catheter. ... represents an innovative new approach to dilatation. ... the two wires to create expansion planes ... challenging lesions. ,The FX miniRAIL RX PTCA ...
... intravascular catheters provide a simple, efficient ... pressures in the heart or cardiovascular ... are ideal for high fidelity pressure ... from 2 to 7 French and ...
... Millar Mikro-Tip pressure intravascular catheters ... accurate method of measuring pressures in ... reusable, thromboresistant Mikro-Tip catheters are ideal ... catheters range in size from 2 ...
... pressure sensor catheters incorporate a ... injection/guide wire, or high-speed injection/guide ... high-speed injection has two laterally ... an open-end pigtail extension for ...
Medicine Products: